Proqr Therapeuti Stock Price, News & Analysis

ProQR Therapeutics reported Q3 2020 results, emphasizing clinical trial advancements and financial stability. The Illuminate Phase 2/3 trial of sepofarsen is projected to complete enrollment in Q1 2021. Data from the QR-421a and QR-1123 trials is expected in 2021, with the QR-504a study on Fuchs to begin in H1 2021. Financially, cash reserves stand at €88.8 million, with a net loss of €13.2 million for the quarter. The company’s runway extends into 2023 due to strategic financing agreements.

ProQR Therapeutics (Nasdaq: PRQR) announced virtual presentations at the American Academy of Ophthalmology Annual Meeting from November 13-15, 2020. Findings will include Phase 1b/2 trial results of sepofarsen for Leber congenital amaurosis 10 (LCA10), presented by Stephen R. Russell, MD. Another presentation by Allen Ho, MD, will focus on patient responses assessed via full-field stimulus testing. Sepofarsen is a pivotal RNA therapy targeting the p.Cys998X mutation in the CEP290 gene, designed to restore normal protein function and has received several designations from health authorities.

ProQR Therapeutics has appointed Naveed Shams, MD, PhD as its new Chief Scientific Officer, succeeding David Rodman, MD. Dr. Shams, with over 20 years of experience in ophthalmology, previously held prominent roles at Santen and Genentech, where he contributed to key drug developments like Lucentis. His expertise will focus on enhancing ProQR's research and development of innovative RNA therapies for inherited retinal diseases. David Rodman will assist during the transition in an advisory capacity.

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced virtual presentations at key ophthalmology forums, focusing on advancements in treatments for inherited retinal diseases. Highlights include:

• Ophthalmology Futures Retina Forum: Presentation on managing inherited retinal diseases by CMO Aniz Girach on September 30, 2020.
• Euretina Congress: Results from Phase 1b/2 trial of sepofarsen in Leber congenital amaurosis (LCA10) presented by Stephen R. Russell, available from October 2, 2020.
• AAOpt Meeting: Discussion on early genetic diagnosis and patient referrals in retinal diseases on October 7, 2020.

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced participation in several upcoming investor conferences aimed at discussing its focus on RNA medicines for inherited retinal diseases. Key events include the Citi's 15th Annual BioPharma Virtual Conference on September 10, the H.C. Wainwright 22nd Annual Conference on September 15, the Cantor Virtual Global Healthcare Conference on September 16, and the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6. Details of the presentations can be found on the company's website, with archived webcasts available post-presentation.

ProQR Therapeutics (Nasdaq: PRQR) reported positive preliminary data from the InSight extension study of sepofarsen for LCA10, reinforcing confidence in the Phase 2/3 Illuminate trial. A strategic convertible debt financing extends the company’s runway into 2023. ProQR is actively enrolling patients across three clinical-stage RNA therapies, with a fourth program set for clinical testing. Financially, cash and cash equivalents stood at €87.1 million, while net cash used in operating activities was €10.5 million. The net loss for Q2 2020 was €4.1 million, down from €11.7 million in the prior year.

ProQR Therapeutics (Nasdaq: PRQR) has enhanced its Scientific Advisory Board (SAB) with the addition of leading experts in inherited retinal disease and RNA therapies. This strategic move aims to support the advancement of ProQR's RNA therapeutics pipeline. CEO Daniel A. de Boer expressed optimism about the diverse perspectives these experts will contribute. The SAB includes notable figures like James Shannon, Mike Cheetham, and Thaddeus Drija, among others, who collectively bring significant experience in the fields of ophthalmology and RNA drug development.

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced a $30 million convertible debt financing agreement with Pontifax Medison Debt Financing to enhance financial flexibility and extend its cash runway into 2023. The deal allows Pontifax to convert the debt into equity at $7.88 per share, a 50% premium to the average share price prior to the agreement. This funding is expected to accelerate the company's RNA therapy pipeline for severe genetic diseases. The financing will occur in three tranches, maturing over 54 months with an initial interest-only period of 24 months.

ProQR Therapeutics (Nasdaq: PRQR) will host an Expert Perspectives call on July 20, 2020, at 5:00 PM EDT, focusing on Leber congenital amaurosis 10 (LCA10) and investigational RNA therapy, sepofarsen. The call will showcase new preliminary data from the ongoing InSight Phase 1/2 extension study, particularly concerning second-eye treatment. Aniz Girach, MD, and Ian MacDonald, MD, will present and interpret the data. Sepofarsen, designed to address the p.Cys998X mutation in the CEP290 gene, has shown promising results with significant vision improvements in trials.